Novel SARS-CoV-2 variants: the pandemics within the pandemic

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

(2021) Lewis F. Buss et al.   SCIENCE

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

(2021) Wilfredo F. Garcia-Beltran et al.   CELL

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs

(2021) Paolo Calistri et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Emergence of a Novel SARS-CoV-2 Variant in Southern California

(2021) Wenjuan Zhang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

(2021) Kevin R. McCarthy et al.   SCIENCE

Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck

(2021) Katarina M. Braun et al.   PLoS Pathogens

Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco

(2021) James Peng et al.   CLINICAL INFECTIOUS DISEASES

Enhanced binding of the N501Y‐mutated SARS‐CoV‐2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

(2021) Binquan Luan et al.   FEBS LETTERS

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

(2021) Katherine R W Emary et al.   LANCET

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

(2021) Dan Frampton et al.   LANCET INFECTIOUS DISEASES

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

(2021) Thandeka Moyo-Gwete et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

(2021) Mark S Graham et al.   Lancet Public Health

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

(2020) Andrew Rambaut et al.   Nature Microbiology

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

(2020) Barnaby E Young et al.   LANCET

Phylogenetic and phylodynamic analyses of SARS-CoV-2

(2020) Qing Nie et al.   VIRUS RESEARCH

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

(2020) Erik Volz et al.   CELL

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

(2020) Allison J. Greaney et al.   Cell Host & Microbe